A monumental, decades-spanning analysis encompassing 54 randomized controlled trials has yielded substantial findings regarding the therapeutic efficacy of medicinal cannabis, particularly concerning prevalent mental health disorders. Published in the esteemed journal The Lancet, this extensive research systematically evaluates the safety and effectiveness of cannabinoid-based treatments across a broad spectrum of psychological conditions. The overarching conclusion is that current evidence provides no demonstrable support for the use of medicinal cannabis in treating anxiety, depression, or post-traumatic stress disorder (PTSD). This significant global undertaking, drawing data from research conducted between 1980 and 2025, offers a robust, evidence-based perspective at a time when self-reported medical cannabis use for mental health symptoms is alarmingly widespread. In nations like the United States and Canada, nearly a third of adults between 16 and 65 years of age have reported utilizing cannabis for medical purposes, with a considerable proportion citing its use to manage psychological distress.
The implications of these findings are profound, especially for clinical practice and regulatory frameworks surrounding medicinal cannabis. Dr. Jack Wilson, the lead author of the study and a researcher at the University of Sydney’s Matilda Centre, articulated the critical questions raised by the data concerning the approval and prescription of cannabis for conditions such as anxiety, depression, and PTSD. Dr. Wilson cautioned that the pervasive, often unmonitored use of medicinal cannabis for these ailments might inadvertently be causing more harm than good. He elaborated on the potential for adverse outcomes, including an increased susceptibility to psychotic symptoms, the development of cannabis use disorder, and the critical risk of patients delaying or foregoing the utilization of treatments that have proven efficacy. This sentiment underscores a growing concern within the medical community about the potential for therapeutic substitution, where less effective or potentially harmful interventions are chosen over established treatments due to perceived accessibility or anecdotal benefits.
While the study unequivocally casts doubt on the utility of medicinal cannabis for core mental health disorders, it does acknowledge some, albeit weak, indications of potential benefit in other specific domains. These include conditions such as cannabis use disorder itself (often referred to as cannabis dependency), certain symptoms associated with autism spectrum disorder, insomnia, and involuntary muscle spasms known as tics, including Tourette’s syndrome. However, Dr. Wilson was emphatic in highlighting the low quality of evidence supporting these ancillary applications. He stressed that in the absence of comprehensive medical or psychological support, the justification for employing medicinal cannabis in these contexts is frequently tenuous.
The research team drew a clear distinction between the evidence base for mental health conditions and that for well-established pharmaceutical applications of cannabinoids. They noted that existing research does support the use of medicinal cannabis for conditions with a more direct neurological or physiological basis, such as reducing seizure frequency in specific forms of epilepsy, alleviating spasticity in individuals with multiple sclerosis, and managing certain types of chronic pain. Yet, the current study’s findings emphatically demonstrate that the evidence for mental health disorders simply does not meet this threshold of established therapeutic value. Regarding the specific case of autism, while a modicum of evidence suggested a potential for symptom reduction, the authors strongly advised caution. They underscored the inherent variability in the autistic experience, emphasizing that a universal or singular response to any intervention, including medicinal cannabis, is highly improbable and thus requires careful, individualized assessment.
The complex relationship between medicinal cannabis and substance use disorders was another focal point of the investigation, revealing nuanced and sometimes contradictory outcomes. The review indicated that cannabis-based treatments might offer some promise in assisting individuals struggling with cannabis dependence, mirroring strategies used for other substance use disorders where a substitute medication can help manage withdrawal and cravings. However, a particularly concerning finding emerged regarding individuals with cocaine-use disorder, where the use of cannabis was observed to intensify cravings for cocaine. This dichotomy highlights the need for highly specific and context-dependent therapeutic considerations when evaluating cannabinoid interventions.
Dr. Wilson elaborated on the potential role of cannabis medicines in treating cannabis use disorder, drawing a parallel to the established practice of using methadone to manage opioid dependence. He explained that when administered in conjunction with psychological therapies, an orally administered formulation of cannabis demonstrated an ability to reduce the frequency of cannabis smoking. This suggests a potential harm reduction strategy. Conversely, the study’s findings concerning cocaine-use disorder present a stark warning. The observed increase in cravings for cocaine when medicinal cannabis was used as a treatment highlights a significant contraindication, suggesting that it should not be considered for this purpose and could, in fact, exacerbate cocaine dependence. This underscores the critical importance of understanding the pharmacological interactions and potential adverse effects across different substance use profiles.
The escalating trend in the prescription and self-administration of medicinal cannabis has understandably prompted significant apprehension among leading medical organizations globally, including the American Medical Association. A primary driver of this concern is the perceived inadequacy of regulatory oversight and the persistent uncertainty surrounding the true efficacy and safety profiles of these widely available products. The comprehensive nature of this research, characterized as a systematic review and meta-analysis, is intended to provide clinicians with a consolidated and independent assessment of the benefits and risks associated with cannabis medicines. Dr. Wilson articulated that the study’s aim is to empower healthcare providers to make decisions grounded in robust scientific evidence, thereby ensuring that patients receive treatments that are both effective and safe, while simultaneously minimizing exposure to products that are either ineffective or potentially harmful.
The foundational data for this landmark study was meticulously compiled from 54 randomized controlled trials, representing a significant global effort to scrutinize the scientific literature on medicinal cannabis. These trials, conducted across diverse geographical locations, spanned an extensive period of 45 years, from 1980 to 2025, providing a comprehensive historical and contemporary perspective. The research received vital funding from the National Health and Medical Research Council (NHMRC). The authors disclosed potential conflicts of interest, with Wayne Hall and Myfanwy Graham having received consultation fees from the World Health Organization. Wayne Hall also reported receiving payment for expert testimony related to the risks associated with cannabis use. Myfanwy Graham holds a position as a member of the Medicinal Cannabis Expert Working Group for the Australian Department of Health, Ageing and Disability, and has also received funding from the Therapeutic Goods Administration for independent reviews of medicinal cannabis evidence. All other co-authors declared no competing interests, reinforcing the study’s commitment to impartiality. This rigorous methodology and transparent disclosure process lend considerable weight to the study’s conclusions, urging a re-evaluation of current practices and a more cautious, evidence-driven approach to medicinal cannabis in clinical settings.
About the Author
